NCT02143388

Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Zhao Chong · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an randomized controlled, multicenter clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of concurrent cisplatin chemoradiation with or without capecitabine as adjuvant chemotherapy in local advanced high risk nasopharyngeal carcinoma.

Conditions

• Local Advanced High Risk Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	IMRT combine with cisplatin concurrent chemotherapy	Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
DRUG	IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy	Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.

Timeline

• Start date: 2014-03-31
• Primary completion: 2018-07-27
• Completion: 2022-08-05
• First posted: 2014-05-21
• Last updated: 2022-08-31

Locations

1 site across 1 country: China